Navigation Links
SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases
Date:12/14/2011

MENLO PARK, Calif., Dec. 14, 2011 /PRNewswire/ -- SRI International has been awarded a contract worth up to $100.5 million over 10 years from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).  This new award will allow SRI to continue a program that supports NIAID's Division of Microbiology and Infectious Diseases (DMID) in the translation of basic research into clinical applications. Since 2006, SRI has worked on more than 100 DMID projects to advance therapeutics for a broad range of infectious diseases, including tuberculosis, malaria, Chagas disease, methicillin-resistant Staph aureus (MRSA), and broad-spectrum antibacterial, antifungal, and antiviral agents. 

This contract supports preclinical development of drugs to treat a wide range of diseases caused by bacteria, fungi, viruses, parasites, toxins, drug-resistant organisms, and bioterrorism agents. As part of the new award, SRI will provide services in four major areas to move potential drugs from early-stage discovery to clinical assessment: drug discovery support; formulation development, analytical chemistry, and clinical manufacturing; toxicology and pharmacology; and regulatory assessment and product feasibility.

"SRI is honored to have been selected to perform this important work to further advance the DMID translational program," said Jon Mirsalis, Ph.D., D.A.B.T., managing director of SRI's Biosciences Division and principal investigator of this program. "SRI has been advancing cures for infectious disease for more than four decades, and our deep insight into the management and conduct of efficient and productive preclinical drug development programs will contribute to the important goals of the DMID program."

SRI has been the major contractor to NIAID for the preclinical development of interventional agents for infectious diseases since the AIDS therapeutic development program began at NIAID in 1991. SRI holds similar development programs with the NCI, NHLBI, NIA, NIMH, NICHD, NINDS, and NIDA, making it the largest provider of preclinical resources to the NIH.

This project will be been funded in whole with Federal funds from the National institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN2722011000221

About SRI's Biosciences Division

SRI's Biosciences Division carries out basic research, drug discovery, and drug development, and provides contract services. SRI has all of the resources necessary to take R&D from Idea to IND®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and other clients and partners advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International, a nonprofit research and development organization, performs sponsored R&D for governments, businesses, and foundations. SRI brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Commemorating its 65th anniversary in 2011, SRI is known for world-changing innovations in computing, health and pharmaceuticals, chemistry and materials, sensing, energy, education, national defense, and more.


'/>"/>
SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- Nevro Corp. (NYSE: NVRO), a global medical device company ... chronic pain, today reported financial results for the three months ... 2016 Accomplishment & Highlights: Achieved revenue of ... 228% as reported, over the prior year U.S. ... over the prior year International revenue of ...
(Date:2/23/2017)... REDWOOD CITY, Calif. , Feb. 23, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that it will release ... close on Thursday, March 2nd, 2017. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Los ... two episodes of WE TV’s “Mama June: From Not to Hot,” which will begin ... notable, “Mama” June Shannon, known to millions from the 2012 reality television series, “Here ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, ... Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist by ... directory that recognizes local physicians and dentists who have earned high ratings and superior ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... ... 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior Lake, ... the Minneapolis Home and Garden Show which is being held February 24 through 26 ... is the Minneapolis Convention Center. , From its broad line of sit stand ...
Breaking Medicine News(10 mins):